Comparative Pharmacology
Head-to-head clinical analysis: BISOPROLOL FUMARATE versus COREG CR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BISOPROLOL FUMARATE versus COREG CR.
BISOPROLOL FUMARATE vs COREG CR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist; reduces cardiac output, heart rate, and renin release from kidneys.
Nonselective beta-1, beta-2, and alpha-1 adrenergic receptor antagonist; no intrinsic sympathomimetic activity; reduces myocardial oxygen demand, decreases peripheral vascular resistance, and suppresses renin-angiotensin-aldosterone system.
Adults: Initial dose 2.5-5 mg orally once daily, titrate to 10 mg once daily; maximum 20 mg once daily.
Initial dose 20 mg orally once daily for patients with heart failure; may increase at 2-week intervals to a target dose of 80 mg once daily.
None Documented
None Documented
Terminal elimination half-life is 9–12 hours (mean 11 hours), allowing once-daily dosing. Half-life may be prolonged in renal impairment (creatinine clearance <40 mL/min) and in elderly patients.
Terminal elimination half-life is 7-10 hours; due to controlled-release formulation, effective half-life is prolonged to support once-daily dosing
Approximately 50% excreted unchanged in urine; remainder metabolized in liver to inactive metabolites, then renally excreted. Fecal excretion is negligible (<2%). Total renal clearance accounts for ~60-70% of elimination.
Renal (16% unchanged, 60% as glucuronide conjugates), biliary/fecal (20%)
Category C
Category C
Beta-Blocker
Beta-Blocker